133 related articles for article (PubMed ID: 19263294)
1. Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.
Blum KA; Hamadani M; Phillips GS; Lozanski G; Johnson AJ; Lucas DM; Smith LL; Baiocchi R; Lin TS; Porcu P; Devine SM; Byrd JC
Leuk Lymphoma; 2009 Mar; 50(3):349-56. PubMed ID: 19263294
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
[TBL] [Abstract][Full Text] [Related]
3. Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study.
Abramson JS; Takvorian RW; Fisher DC; Feng Y; Jacobsen ED; Brown JR; Barnes JA; Neuberg DS; Hochberg EP
Leuk Lymphoma; 2013 Sep; 54(9):1915-20. PubMed ID: 23289359
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.
Nabhan C; Davis N; Bitran JD; Galvez A; Fried W; Tolzien K; Foss S; Dewey WM; Venugopal P
Cancer; 2011 Apr; 117(7):1490-7. PubMed ID: 21425150
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Seymour JF; Grigg AP; Szer J; Fox RM
Cancer; 2002 Feb; 94(3):585-93. PubMed ID: 11857288
[TBL] [Abstract][Full Text] [Related]
7. Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.
Younes A; Salles G; Martinelli G; Bociek RG; Barrigon DC; Barca EG; Turgut M; Gerecitano J; Kong O; Pisal CB; Tavorath R; Kim WS
Haematologica; 2017 Dec; 102(12):2104-2112. PubMed ID: 28971900
[TBL] [Abstract][Full Text] [Related]
8. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.
Bennani NN; LaPlant BR; Ansell SM; Habermann TM; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Colgan JP; Markovic SN; Nowakowski GS; Macon WR; Reeder CB; Mikhael JR; Northfelt DW; Ghobrial IM; Witzig TE
Am J Hematol; 2017 May; 92(5):448-453. PubMed ID: 28211162
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.
Jeha S; Razzouk B; Rytting M; Rheingold S; Albano E; Kadota R; Luchtman-Jones L; Bomgaars L; Gaynon P; Goldman S; Ritchey K; Arceci R; Altman A; Stine K; Steinherz L; Steinherz P
J Clin Oncol; 2009 Sep; 27(26):4392-7. PubMed ID: 19652076
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.
Koh K; Ogawa C; Okamoto Y; Kudo K; Inagaki J; Morimoto T; Mizukami H; Ecstein-Fraisse E; Kikuta A
Int J Hematol; 2016 Aug; 104(2):245-55. PubMed ID: 27086352
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Haq R; Sawka CA; Franssen E; Berinstein NL
Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
[TBL] [Abstract][Full Text] [Related]
15. Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma.
Zoellner AK; Fritsch S; Prevalsek D; Engel N; Hubmann M; Reibke R; Rieger CT; Hellmuth JC; Haas M; Mumm F; Herold T; Ledderose G; Hiddemann W; Dreyling M; Hausmann A; Tischer J
Bone Marrow Transplant; 2015 May; 50(5):679-84. PubMed ID: 25642765
[TBL] [Abstract][Full Text] [Related]
16. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.
Magenau J; Tobai H; Pawarode A; Braun T; Peres E; Reddy P; Kitko C; Choi S; Yanik G; Frame D; Harris A; Erba H; Kujawski L; Elenitoba-Johnson K; Sanks J; Jones D; Paczesny S; Ferrara J; Levine J; Mineishi S
Blood; 2011 Oct; 118(15):4258-64. PubMed ID: 21841163
[TBL] [Abstract][Full Text] [Related]
17. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease.
Simko SJ; Tran HD; Jones J; Bilgi M; Beaupin LK; Coulter D; Garrington T; McCavit TL; Moore C; Rivera-Ortegón F; Shaffer L; Stork L; Turcotte L; Welsh EC; Hicks MJ; McClain KL; Allen CE
Pediatr Blood Cancer; 2014 Mar; 61(3):479-87. PubMed ID: 24106153
[TBL] [Abstract][Full Text] [Related]
18. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
19. Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa.
Spitzer B; Perales MA; Kernan NA; Prockop SE; Zabor EC; Webb N; Castro-Malaspina H; Papadopoulos EB; Young JW; Scaradavou A; Kobos R; Giralt SA; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1449-1454. PubMed ID: 27184623
[TBL] [Abstract][Full Text] [Related]
20. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
Steinherz PG; Shukla N; Kobos R; Steinherz L
Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
